Ningbo Menovo TianKang Pharmaceutical Co., Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation domenorrhea tablets (2 mg, manufactured by Ningbo Minova Tiankang Pharmaceutical Co., Ltd.) and the reference formulation domenorrhea tablets (URECE®, 2 mg, manufactured by Fuji Pharmaceutical Co., Ltd.) in healthy adult participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test formulation domenorrhea tablets (2 mg) and the reference formulation domenorrhea tablets (URECE®, 2 mg) in healthy adult participants.

This study aimed to investigate the pharmacokinetic characteristics of mirtazapine hydrochloride tablets (50 mg) developed and manufactured by Ningbo Minova Tiankang Pharmaceutical Co., Ltd., after a single oral fasting dose. Minapril hydrochloride tablets (Toledomin®, 50 mg) manufactured by Asahi Kasei Corporation (Asahi Kasei Pharmaceutical Co., Ltd.) were used as the reference formulation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their bioequivalence in humans.

This study aimed to investigate the pharmacokinetic characteristics of melogabalin besylate tablets (5 mg) developed and manufactured by Ningbo Minova Tiankang Pharmaceutical Co., Ltd., after a single fasting and postprandial oral administration. Melogabalin besylate tablets (Tarlige®, 5 mg), licensed by DAIICHI SANKYO CO., LTD. and manufactured by TAIYO Pharma Tech CO., LTD., Takatsuki Plant, were used as the reference formulation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their bioequivalence in humans.